Share Price and Basic Stock Data
Last Updated: February 6, 2026, 8:54 pm
| PEG Ratio | 0.78 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Indraprastha Medical Corporation Ltd operates within the Hospitals & Medical Services industry and has exhibited robust growth in its revenue streams. For the financial year ending March 2025, the company reported sales of ₹1,356 Cr, up from ₹1,245 Cr in March 2024, marking a year-on-year growth rate of approximately 8.9%. Quarterly sales figures also demonstrate a consistent upward trajectory, with the latest quarter ending September 2023 reporting sales of ₹317 Cr, compared to ₹284 Cr in September 2022. This indicates a healthy growth trend, reflective of increased healthcare demand and operational efficiency. The company’s market capitalization stands at ₹3,446 Cr, with a price-to-earnings (P/E) ratio of 19.7, positioning it competitively within the sector. Additionally, the company’s operating profit margin (OPM) has improved to 18% for March 2025, which is above the industry average, suggesting effective cost management and operational excellence. Overall, the revenue trends indicate a solid business foundation and a proactive approach to capturing market opportunities.
Profitability and Efficiency Metrics
Indraprastha Medical Corporation has demonstrated strong profitability metrics, characterized by a return on equity (ROE) of 30.0% and a return on capital employed (ROCE) of 39.1% for March 2025. These figures are significantly higher than typical sector averages, indicating effective utilization of equity and capital for generating profits. The net profit for the same period was recorded at ₹161 Cr, up from ₹124 Cr in March 2024, showcasing a robust growth trajectory. The company also reported an interest coverage ratio of 42.57x, reflecting its strong ability to meet interest obligations, which is a positive indicator of financial health. Furthermore, the cash conversion cycle (CCC) stood at 20 days, indicating efficient management of receivables and payables. However, the operating profit margin (OPM) for the latest fiscal year is 18%, which, while strong, could be enhanced further to align with top-tier competitors in the industry. Overall, these metrics highlight Indraprastha’s operational efficiency and its commitment to maximizing shareholder value.
Balance Sheet Strength and Financial Ratios
The balance sheet of Indraprastha Medical Corporation reflects considerable strength, with total assets amounting to ₹852 Cr as of March 2025, up from ₹723 Cr the previous year. The company’s equity capital remains stable at ₹92 Cr, while reserves have increased to ₹505 Cr, demonstrating a robust capacity for reinvestment and growth. The total borrowings, however, stood at ₹33 Cr, indicating prudent financial leverage. The company’s debt-to-equity ratio remains low, suggesting a conservative approach to financing, which is advantageous in maintaining financial stability. The book value per share has also improved to ₹65.09, compared to ₹52.12 in March 2024, further enhancing shareholder equity. The current ratio of 2.41x indicates good liquidity, ensuring that the company can cover its short-term liabilities comfortably. Such strong financial ratios and a solid balance sheet position Indraprastha favorably for future growth while minimizing financial risks.
Shareholding Pattern and Investor Confidence
Indraprastha Medical Corporation’s shareholding structure showcases a balanced distribution, with promoters holding 51.00% of the equity, which reflects strong insider confidence in the company’s future. Foreign institutional investors (FIIs) have gradually increased their stake to 2.41% as of September 2025, up from 0.77% in December 2022, indicating growing interest from international investors. Domestic institutional investors (DIIs) have also shown positive engagement, with their holdings at 3.51%. The public shareholding stood at 43.08%, indicating a broad base of retail investors. The total number of shareholders has risen to 70,914, signaling increased investor confidence and interest in the company’s growth story. This diverse shareholding pattern aids in liquidity and market stability, while the increasing participation of FIIs suggests a favorable outlook on the company’s performance and prospects. Overall, the shareholding dynamics reflect strong investor confidence, which is crucial for long-term sustainability.
Outlook, Risks, and Final Insight
Indraprastha Medical Corporation’s outlook appears promising, bolstered by strong revenue growth, robust profitability metrics, and a solid balance sheet. However, the company faces potential risks, including regulatory changes in the healthcare sector that could impact operational costs and profitability. Additionally, increasing competition from both established players and new entrants poses a challenge to maintaining market share. The company’s reliance on domestic operations could also expose it to regional economic fluctuations. Nevertheless, the strengths, including high ROE, efficient operations, and a supportive shareholding structure, position Indraprastha favorably for continued growth. Should the company effectively navigate regulatory challenges and enhance its operational efficiency, it could further solidify its market position. Conversely, failure to adapt to competitive pressures could hinder its growth trajectory. Overall, with prudent management and strategic planning, Indraprastha Medical Corporation is well-placed to capitalize on emerging opportunities in the healthcare sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.9 Cr. | 146 | 187/120 | 9.98 | 117 | 2.40 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 14.9 Cr. | 14.2 | 33.0/13.1 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.4 Cr. | 10.1 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 104 Cr. | 55.2 | 98.7/52.2 | 22.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.2 Cr. | 3.55 | 6.38/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,485.00 Cr | 681.69 | 87.63 | 92.86 | 0.35% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Indraprastha Medical Corporation Ltd
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 277 | 274 | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 | 381 | 372 |
| Expenses | 240 | 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 | 310 | 310 |
| Operating Profit | 37 | 33 | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 | 71 | 62 |
| OPM % | 13% | 12% | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% | 19% | 17% |
| Other Income | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 | 11 | 11 |
| Profit before tax | 29 | 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 | 66 | 56 |
| Tax % | 29% | 27% | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% | 25% | 27% |
| Net Profit | 21 | 20 | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 | 49 | 41 |
| EPS in Rs | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 | 5.40 | 4.47 |
Last Updated: February 5, 2026, 1:08 pm
Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 372.00 Cr.. The value appears to be declining and may need further review. It has decreased from 381.00 Cr. (Sep 2025) to 372.00 Cr., marking a decrease of 9.00 Cr..
- For Expenses, as of Dec 2025, the value is 310.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 310.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Sep 2025) to 62.00 Cr., marking a decrease of 9.00 Cr..
- For OPM %, as of Dec 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 19.00% (Sep 2025) to 17.00%, marking a decrease of 2.00%.
- For Other Income, as of Dec 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 7.00 Cr..
- For Interest, as of Dec 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.00 Cr. (Sep 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Dec 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 11.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Sep 2025) to 56.00 Cr., marking a decrease of 10.00 Cr..
- For Tax %, as of Dec 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2025) to 27.00%, marking an increase of 2.00%.
- For Net Profit, as of Dec 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Sep 2025) to 41.00 Cr., marking a decrease of 8.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 4.47. The value appears to be declining and may need further review. It has decreased from 5.40 (Sep 2025) to 4.47, marking a decrease of 0.93.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 | 1,405 |
| Expenses | 587 | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 | 1,147 |
| Operating Profit | 91 | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 245 | 258 |
| OPM % | 13% | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% | 18% |
| Other Income | 1 | 1 | 1 | -0 | -1 | -1 | -0 | -0 | -3 | 9 | 16 | 22 | 26 |
| Interest | 10 | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 |
| Depreciation | 28 | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 43 |
| Profit before tax | 54 | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 234 |
| Tax % | 35% | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% | |
| Net Profit | 35 | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 | 175 |
| EPS in Rs | 3.87 | 3.54 | 2.66 | 2.86 | 2.30 | 3.10 | 4.76 | 0.25 | 6.39 | 9.40 | 13.52 | 17.56 | 19.06 |
| Dividend Payout % | 47% | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -8.57% | -25.00% | 8.33% | -19.23% | 33.33% | 57.14% | -95.45% | 2850.00% | 45.76% | 44.19% | 29.84% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.43% | 33.33% | -27.56% | 52.56% | 23.81% | -152.60% | 2945.45% | -2804.24% | -1.58% | -14.35% |
Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 58% |
| 3 Years: | 89% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 23% |
| 3 Years: | 28% |
| Last Year: | 30% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 95 | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 567 |
| Borrowings | 63 | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 | 31 |
| Other Liabilities | 199 | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 | 264 |
| Total Liabilities | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
| Fixed Assets | 293 | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 | 351 |
| CWIP | 2 | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 |
| Other Assets | 154 | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 | 563 |
| Total Assets | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 92.00 Cr..
- For Reserves, as of Sep 2025, the value is 567.00 Cr.. The value appears strong and on an upward trend. It has increased from 505.00 Cr. (Mar 2025) to 567.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 264.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 222.00 Cr. (Mar 2025) to 264.00 Cr., marking an increase of 42.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 39.00 Cr..
- For Other Assets, as of Sep 2025, the value is 563.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Mar 2025) to 563.00 Cr., marking an increase of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 954.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
Notably, the Reserves (567.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 35.00 | 28.00 | 12.00 | 8.00 | 61.00 | 83.00 | 38.00 | 115.00 | 150.00 | 161.00 | 212.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Working Capital Days | -27 | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 |
| ROCE % | 26% | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 721,778 | 0.14 | 43.77 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Diluted EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Cash EPS (Rs.) | 22.40 | 17.89 | 13.68 | 10.21 | 3.89 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Dividend / Share (Rs.) | 4.50 | 4.50 | 3.00 | 2.50 | 0.00 |
| Revenue From Operations / Share (Rs.) | 147.96 | 135.78 | 119.85 | 96.89 | 66.91 |
| PBDIT / Share (Rs.) | 29.12 | 22.93 | 17.53 | 12.81 | 4.47 |
| PBIT / Share (Rs.) | 24.28 | 18.56 | 13.25 | 9.00 | 0.83 |
| PBT / Share (Rs.) | 23.60 | 18.12 | 12.78 | 8.63 | 0.46 |
| Net Profit / Share (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| PBDIT Margin (%) | 19.67 | 16.89 | 14.62 | 13.22 | 6.67 |
| PBIT Margin (%) | 16.41 | 13.67 | 11.05 | 9.28 | 1.24 |
| PBT Margin (%) | 15.94 | 13.34 | 10.66 | 8.90 | 0.69 |
| Net Profit Margin (%) | 11.86 | 9.95 | 7.84 | 6.60 | 0.37 |
| Return on Networth / Equity (%) | 26.98 | 25.94 | 22.70 | 18.01 | 0.85 |
| Return on Capital Employeed (%) | 33.07 | 30.50 | 28.54 | 22.40 | 2.41 |
| Return On Assets (%) | 18.90 | 17.13 | 15.51 | 12.69 | 0.53 |
| Asset Turnover Ratio (%) | 1.72 | 1.95 | 2.16 | 1.99 | 1.39 |
| Current Ratio (X) | 2.41 | 1.86 | 1.72 | 1.68 | 1.22 |
| Quick Ratio (X) | 2.37 | 1.82 | 1.66 | 1.58 | 1.14 |
| Inventory Turnover Ratio (X) | 186.83 | 0.00 | 21.00 | 18.55 | 10.95 |
| Dividend Payout Ratio (NP) (%) | 25.62 | 22.18 | 26.60 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20.09 | 16.76 | 18.27 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 74.38 | 77.82 | 73.40 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 79.91 | 83.24 | 81.73 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 42.57 | 51.79 | 37.55 | 34.43 | 12.27 |
| Interest Coverage Ratio (Post Tax) (X) | 26.68 | 31.53 | 21.13 | 18.19 | 1.70 |
| Enterprise Value (Cr.) | 3217.17 | 1350.00 | 583.80 | 467.36 | 465.22 |
| EV / Net Operating Revenue (X) | 2.37 | 1.08 | 0.53 | 0.52 | 0.75 |
| EV / EBITDA (X) | 12.05 | 6.42 | 3.63 | 3.98 | 11.36 |
| MarketCap / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| Retention Ratios (%) | 74.37 | 77.81 | 73.39 | 0.00 | 0.00 |
| Price / BV (X) | 5.93 | 3.30 | 1.88 | 1.65 | 1.81 |
| Price / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| EarningsYield | 0.04 | 0.07 | 0.12 | 0.10 | 0.00 |
After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.40. This value is within the healthy range. It has increased from 17.89 (Mar 24) to 22.40, marking an increase of 4.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Dividend / Share (Rs.), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 4.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 147.96. It has increased from 135.78 (Mar 24) to 147.96, marking an increase of 12.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 29.12. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 29.12, marking an increase of 6.19.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 18.56 (Mar 24) to 24.28, marking an increase of 5.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 18.12 (Mar 24) to 23.60, marking an increase of 5.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 19.67. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 19.67, marking an increase of 2.78.
- For PBIT Margin (%), as of Mar 25, the value is 16.41. This value is within the healthy range. It has increased from 13.67 (Mar 24) to 16.41, marking an increase of 2.74.
- For PBT Margin (%), as of Mar 25, the value is 15.94. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 15.94, marking an increase of 2.60.
- For Net Profit Margin (%), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 10. It has increased from 9.95 (Mar 24) to 11.86, marking an increase of 1.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 26.98. This value is within the healthy range. It has increased from 25.94 (Mar 24) to 26.98, marking an increase of 1.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 33.07. This value is within the healthy range. It has increased from 30.50 (Mar 24) to 33.07, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 18.90. This value is within the healthy range. It has increased from 17.13 (Mar 24) to 18.90, marking an increase of 1.77.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.72. It has decreased from 1.95 (Mar 24) to 1.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 1.86 (Mar 24) to 2.41, marking an increase of 0.55.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 1.82 (Mar 24) to 2.37, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 186.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 186.83, marking an increase of 186.83.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 25.62. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 25.62, marking an increase of 3.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.09. This value is within the healthy range. It has increased from 16.76 (Mar 24) to 20.09, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 74.38. This value exceeds the healthy maximum of 70. It has decreased from 77.82 (Mar 24) to 74.38, marking a decrease of 3.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.91. This value exceeds the healthy maximum of 70. It has decreased from 83.24 (Mar 24) to 79.91, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 42.57. This value is within the healthy range. It has decreased from 51.79 (Mar 24) to 42.57, marking a decrease of 9.22.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.68. This value is within the healthy range. It has decreased from 31.53 (Mar 24) to 26.68, marking a decrease of 4.85.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,217.17. It has increased from 1,350.00 (Mar 24) to 3,217.17, marking an increase of 1,867.17.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 2.37, marking an increase of 1.29.
- For EV / EBITDA (X), as of Mar 25, the value is 12.05. This value is within the healthy range. It has increased from 6.42 (Mar 24) to 12.05, marking an increase of 5.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For Retention Ratios (%), as of Mar 25, the value is 74.37. This value exceeds the healthy maximum of 70. It has decreased from 77.81 (Mar 24) to 74.37, marking a decrease of 3.44.
- For Price / BV (X), as of Mar 25, the value is 5.93. This value exceeds the healthy maximum of 3. It has increased from 3.30 (Mar 24) to 5.93, marking an increase of 2.63.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
- Net Profit Margin: 11.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 33.07% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 26.98% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.68
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19 (Industry average Stock P/E: 87.63)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Sarita Vihar, New Delhi Delhi 110076 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Vice Chairman |
| Mr. Shivakumar Pattabhiraman | Managing Director |
| Mr. Sudhir Jalan | Director |
| Prof. (Dr) Mahesh Verma | Director |
| Mr. Salil Singhal | Director |
| Dr.(Ms.) Suneeta Reddy | Director |
| Mr. Vinayak Chatterjee | Director |
| Ms. Vineeta Rai | Director |
| Mr. Sandip Somany | Director |
| Mr. Tejpreet Singh Chopra | Director |
| Ms. Madhumita Ganguli | Director |
| Dr.(Ms.) Sangita Reddy | Director |
FAQ
What is the intrinsic value of Indraprastha Medical Corporation Ltd?
Indraprastha Medical Corporation Ltd's intrinsic value (as of 07 February 2026) is ₹412.24 which is 9.06% higher the current market price of ₹378.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,471 Cr. market cap, FY2025-2026 high/low of ₹641/307, reserves of ₹567 Cr, and liabilities of ₹954 Cr.
What is the Market Cap of Indraprastha Medical Corporation Ltd?
The Market Cap of Indraprastha Medical Corporation Ltd is 3,471 Cr..
What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 07 February 2026?
The current stock price of Indraprastha Medical Corporation Ltd as on 07 February 2026 is ₹378.
What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indraprastha Medical Corporation Ltd stocks is ₹641/307.
What is the Stock P/E of Indraprastha Medical Corporation Ltd?
The Stock P/E of Indraprastha Medical Corporation Ltd is 19.0.
What is the Book Value of Indraprastha Medical Corporation Ltd?
The Book Value of Indraprastha Medical Corporation Ltd is 71.8.
What is the Dividend Yield of Indraprastha Medical Corporation Ltd?
The Dividend Yield of Indraprastha Medical Corporation Ltd is 1.19 %.
What is the ROCE of Indraprastha Medical Corporation Ltd?
The ROCE of Indraprastha Medical Corporation Ltd is 39.1 %.
What is the ROE of Indraprastha Medical Corporation Ltd?
The ROE of Indraprastha Medical Corporation Ltd is 30.0 %.
What is the Face Value of Indraprastha Medical Corporation Ltd?
The Face Value of Indraprastha Medical Corporation Ltd is 10.0.